Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IC14 in Sepsis-Induced Acute Lung Injury
NCT00233207Phase 2Terminated
- Sponsor
- University of Washington
- Start
- Sep 2005
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atibuclimab in acute lung injury (ALI), sponsored by University of Washington. Started Sep 2005; status: terminated.
02
Drugs
atibuclimab
03
Conditions
acute lung injury (ALI)
Beyond the preview
Go deeper on NCT00233207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00233207.